Romulus K. Brazzell - 22 Jun 2023 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)

Role
Head of Research and Development and Chief Medical Officer
Signature
/s/ Eric Trachtenberg, Attorney-in-Fact
Issuer symbol
KALA
Transactions as of
22 Jun 2023
Net transactions value
$0
Form type
4
Filing time
23 Jun 2023, 20:00:18 UTC
Previous filing
02 Jun 2023
Next filing
05 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALA Common Stock Award $0 +49,356 +135% $0.000000 85,808 22 Jun 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALA Stock Option (right to buy) Award $0 +65,808 $0.000000 65,808 22 Jun 2023 Common Stock 65,808 $14.56 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026.
F2 Includes 80,256 unvested RSUs.
F3 This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.

Remarks:

Head of Research and Development and Chief Medical Officer